-
Recent advances in the systemic therapy of colorectal cancerŠtabuc, BorutColorectal cancer represents a significant health problem in Europe. Although about fifty percent of patients are cured by surgery alone, the other half will eventually die due to metastatic disease, ... which includes approximately 25% of patients who have evidence of metastases at the time of diagnosis. A sixmonth adjuvant chemotherapy with 5-fluorouracil and leucovorin in Dukes C colon cancer following curative resection has been shown to reduce the risk ofrecurrence by 19-40% and of death by 16-33%. The benefit of adjuvant chemotherapy for the patients with Dukes B colon cancer is less clear. A meta-analysis of 1,381 patients with advanced colorectal cancer showed a significant increase in response rate with the bolus 5-fluorouracil and leucovorin versus 5-fluorouracil alone, but no significant difference in median survival. Continuous infusion allows higher doses of 5-FU than rapid bolus infusion and improves response rate, survival and time to progression. Phase III randomized clinical trials in patients with metastatic colorectal cancer demonstrate the significant superiority of combining irinotecan with 5-fluorouracil and leucovorin or oxaliplatin with 5-fluorouracil and leucovorin over the same 5-fluorouracil and leucovorin alone.Vir: Gastroenterolog : revija Slovenskega združenja za gastroenterologijo in hepatologijo = journal of Slovenian Association for Gastroenterology and Hepatology. - ISSN 1408-2756 (Letn. 7, št. 1, June 2003, str. 32-40)Vrsta gradiva - članek, sestavni delLeto - 2003Jezik - angleškiCOBISS.SI-ID - 16879065
Avtor
Štabuc, Borut
Teme
Colorectal Neoplasms |
Surgery |
Drug Therapy |
Fluorouracil |
Leucovorin |
Disease Progression |
Survival Analysis |
Chemotherapy, Adjuvant |
Interferon Type I |
Antibodies, Monoclonal |
Platinum Compounds |
Camptothecin |
Analogs And Derivatives |
Thymidylate Synthetase |
Antagonists And Inhibitors |
Bolezen, napredovanje |
Fluorouracil |
Kolorektalne novotvorbe |
Levkovorin |
Inteferon tip I |
Kamptotecin |
Kemoterapija pomožna |
Platina, spojine |
Preživetje, analiza |
Protitelesa monoklonska
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Štabuc, Borut | 11949 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.